GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Ezetimibe - single agent

Read renal action and limits

Zetia

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Zetia - product and source limitations

If used with another lipid-lowering drug, verify that drug's dose and renal precautions separately.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Zetia - product and source limitations

Official source

Zetia - labeled renal guidance

Renal action and limits

Ezetimibe (Zetia), oral tablets
Clinical renal category or population named in the cited section

Action or finding
No renal dose adjustment is needed for ezetimibe.
Limits and monitoring
If used with another lipid-lowering drug, verify that drug's dose and renal precautions separately.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 8, effective 2025-11-25; posted Nov 26, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Ezetimibe (Zetia), oral tablets
Renal measure
Clinical renal category or population named in the cited section
Source revision
DailyMed SPL version 8, effective 2025-11-25; posted Nov 26, 2025
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Renal guidance: 8, renal impairment

No renal dose adjustment is needed for ezetimibe. If used with another lipid-lowering drug, verify that drug's dose and renal precautions separately.

Source revision: DailyMed SPL version 8, effective 2025-11-25; posted Nov 26, 2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Handbook

Renal Drug Handbook, 5th edition - Ezetimibe

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Zetia - product and source limitations

If used with another lipid-lowering drug, verify that drug's dose and renal precautions separately.

How to use this: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Handbook source

Renal Drug Handbook, 5th edition - Ezetimibe

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b3842f6-c80a-47b8-8a82-b69e465b05f7

Product and population scope

Adult Ezetimibe - single agent. Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-ezetimibe · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Ezetimibe single-agent tablets - renal dosing

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2024-03-05.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult single-agent ezetimibe: 10 mg orally once daily, with or without food. Renal impairment does not require adjustment. Give at least 2 hours before or 4 hours after a bile-acid sequestrant. Do not apply this single-agent renal statement to a fixed combination without checking the other component's dosing restrictions. The source also identifies cyclosporine-related exposure changes and myopathy precautions.

RDM30-083-ezetimibe-1 · Source locator: Ezetimibe single-agent tablets - renal dosing; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b3842f6-c80a-47b8-8a82-b69e465b05f7
Retrieved
2026-09-05
DailyMed Set ID
5b3842f6-c80a-47b8-8a82-b69e465b05f7
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2024-03-05.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
7a014ad8ff6b12604fd0cf8327bb76dc43262c2b2ecbd98e17b0382558883ad2
Official

Zetia - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Ezetimibe (Zetia), oral tablets

Renal method: Clinical renal category or population named in the cited section
Source date: DailyMed SPL version 8, effective 2025-11-25; posted Nov 26, 2025
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8, renal impairment

No renal dose adjustment is needed for ezetimibe. If used with another lipid-lowering drug, verify that drug's dose and renal precautions separately.

RDM73-zetia-official-1 · Source locator: Renal guidance: 8, renal impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb
Retrieved
2026-11-07
Renal-function method
Clinical renal category or population named in the cited section
Source date/version
DailyMed SPL version 8, effective 2025-11-25; posted Nov 26, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
01548238e98be9f01f1dfa6c12515a9b09743cf690b0f3ece0bc0b9e3e361c9d
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Zetia - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Ezetimibe (Zetia), oral tablets

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror explicitly supports the unadjusted ezetimibe dose in renal impairment.

RDM73-zetia-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zetia-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
d4e8b8a36d0d4a1612dee141f021ba0e88ab116bcc0ca3c14c7e765e9a9da3a2
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Ezetimibe

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. The listed dose is 10 mg orally daily. Dialytic removal is considered unlikely in PD, HD, high-flux and continuous therapy; usual dosing is retained. This applies to ezetimibe itself, not a fixed statin combination.

HB30-ezetimibe-1 · Source locator: Printed page 410: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 410; uploaded PDF p. 429
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b3842f6-c80a-47b8-8a82-b69e465b05f7
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
67076cd5093c652a3fe39d4212d31fbab96a9a7efda89df8c9cdfe3450cca947

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b3842f6-c80a-47b8-8a82-b69e465b05f7
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
fbe0b5c5e21917cf7cf5cbb4f08ce1ab3c365a0154fb8b66e3fa3571af3a43a1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top